Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
118.21
-1.72 (-1.43%)
Nov 9, 2026, 4:00 PM EST - Market closed
Haemonetics Financials Overview
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 26, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Revenue Revenue Growth | 1,382 | 1,334 | 1,361 | 1,309 | 1,169 | 993.2 |
Revenue Growth | 4.11% | -1.97% | 3.96% | 12.01% | 17.67% | 14.10% |
Gross Profit Gross Profit Growth | 826.2 | 792.87 | 778.55 | 708.57 | 622.87 | 530.77 |
Operating Income Operating Income Growth | 260.39 | 251.53 | 247.1 | 205.49 | 167.2 | 105.17 |
Net Income Net Income Growth | 103.91 | 97.31 | 167.68 | 117.56 | 115.4 | 43.38 |
Earnings Per Share EPS Growth | 2.24 | 2.05 | 3.31 | 2.29 | 2.24 | 0.84 |
EPS Growth | -34.84% | -38.07% | 44.54% | 2.23% | 166.67% | -45.81% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 26, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Plasma Plasma Growth | - | 524.46 | 535.43 | 569.54 | 500.49 | 351.95 |
Blood Center Blood Center Growth | - | 221.27 | 261.12 | 283.23 | 289.37 | 294.54 |
Hospital Hospital Growth | - | 588.3 | 564.27 | 456.29 | 378.21 | 321.58 |
Revenue (Total) Revenue (Total) Growth | 1,382 | 1,334 | 1,361 | 1,309 | 1,169 | 993.2 |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 26, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Cash & Investments Cash & Investments Growth | 262.91 | 246.26 | 308.07 | 180.47 | 285.58 | 259.5 |
Total Debt Total Debt Growth | 1,124 | 1,275 | 1,283 | 873.88 | 830.76 | 838.3 |
Net Cash (Debt) Net Cash Growth | -860.85 | -1,028 | -975.28 | -693.41 | -545.18 | -578.81 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -18.56 | -21.72 | -19.22 | -13.49 | -10.60 | -11.27 |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 26, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 344.93 | 293.22 | 181.73 | 181.75 | 273.06 | 172.26 |
Capital Expenditures CapEx Growth | -46.69 | -32.78 | -39.28 | -38.13 | -191.33 | -96.51 |
Free Cash Flow Free Cash Flow Growth | 298.24 | 260.44 | 142.45 | 143.63 | 81.73 | 75.75 |
Free Cash Flow Growth | 16.46% | 82.83% | -0.82% | 75.73% | 7.89% | 5.56% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 26, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Gross Margin | 59.76% | 59.43% | 57.21% | 54.13% | 53.30% | 53.44% |
Operating Margin | 18.83% | 18.86% | 18.16% | 15.70% | 14.31% | 10.59% |
Pretax Margin | 10.27% | 9.60% | 15.58% | 11.60% | 12.10% | 6.41% |
Profit Margin | 7.52% | 7.29% | 12.32% | 8.98% | 9.88% | 4.37% |
FCF Margin | 21.57% | 19.52% | 10.47% | 10.97% | 6.99% | 7.63% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
PE Ratio | 52.81 | 25.81 | 18.93 | 36.87 | 36.17 | 75.24 |
Forward PE | 20.11 | 10.46 | 13.21 | 20.49 | 25.45 | 23.82 |
P/FCF Ratio | 18.05 | 9.64 | 22.29 | 30.18 | 51.08 | 43.08 |
PS Ratio | 3.89 | 1.88 | 2.33 | 3.31 | 3.57 | 3.29 |